Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris 23:55:00 28/08/2026 HKT			5-day change	1st Jan Change
163.10 ^EUR	-3.61%		-0.18%	+37.06%

08-21	Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc.	CI
08-21	Ipsen Wraps Up Purchase of US-based Kartos Therapeutics	MT

Ipsen: Reassessing mid-term risks

Published on 07/06/2026 at 08:00 pm HKT

Alphavalue

This article is reserved for our subscribers.

Alphavalue, the European leader in independent research, is available exclusively on MarketScreener.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Ipsen

08-21	Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc.	CI
08-21	Ipsen Wraps Up Purchase of US-based Kartos Therapeutics	MT
08-21	Ipsen closes the acquisition of Kartos Therapeutics
08-20	Cancer vaccines finally garner the spotlight
08-17	Kepler Cheuvreux Boosts Ipsen PT, Maintains Hold Rating	MT
08-04	Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration	CI
08-03	Jefferies Downgrades Ipsen to Underperform, Boosts PT	MT
08-03	Middle East hopes lift Europe into the green
08-03	European stock markets start August in a good mood
08-01	Ipsen S.A., H1 2026 Earnings Call, Jul 30, 2026
07-30	Ipsen: Another quarterly beat; 2026 guidance upgraded
07-30	Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Ipsen raises its full-year targets
07-30	Ipsen Raises FY26 Sales Growth Outlook	MT
07-30	Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026	CI

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).

Employees

5,535

Sector

Pharmaceuticals

Calendar

10-16 Sales and Revenue Release - Q3 2026

More about the company